B
Barbara A. Goff
Researcher at University of Washington
Publications - 235
Citations - 12862
Barbara A. Goff is an academic researcher from University of Washington. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 61, co-authored 227 publications receiving 11859 citations. Previous affiliations of Barbara A. Goff include Georgetown University & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Patient, physician, and caregiver perspectives on ovarian cancer treatment decision making: lessons from a qualitative pilot study.
TL;DR: This pilot study met its objectives of testing unpaid caregiver recruitment procedures and identifying topics to include in the interview guide for a planned grounded theory study on ovarian cancer treatment decision making.
Journal Article
Large loop excision of the transformation zone in patients with exocervical squamous intraepithelial lesions.
TL;DR: The success of loop excisions is influenced by the grade of intraepithelial neoplasia and status of the margins of the LLETZ specimen, and the number of women with involved margins and women with uninvolved margins.
Journal ArticleDOI
Combined symptom index and second-generation multivariate biomarker test for prediction of ovarian cancer in patients with an adnexal mass
Renata R. Urban,Todd C. Pappas,Rowan G. Bullock,Donald G. Munroe,Vinicius Bonato,Kathy Agnew,Barbara A. Goff +6 more
TL;DR: The combination of a patient-reported symptom index and refined biomarker panel allows for improved accuracy in the assessment for ovarian cancer in patients with an adnexal mass and could offer a personalized approach to addressing ROM.
Journal ArticleDOI
Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium.
TL;DR: The combination of weekly topotecan and gemcitabine is well tolerated, but best response rate is 17%, and confirmed response is only 9%, which is not significantly better than single agent gem citabine or topOTecan.
Journal ArticleDOI
Nonrecommended breast and colorectal cancer screening for young women: a vignette-based survey.
Hajar Kadivar,Hajar Kadivar,Barbara A. Goff,William R. Phillips,C. Holly A. Andrilla,Alfred O. Berg,Laura Mae Baldwin +6 more
TL;DR: A high percentage of physicians report offering non recommended breast or colorectal cancer screening tests for young women, and even physicians who estimated the patient to be at the same risk as the general population reported offering nonrecommended screening tests.